Glenmark Pharmaceuticals has launched Apremilast, the first advanced oral systemic treatment for Psoriasis in India. The drug is phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of moderate to severe Psoriasis. It is estimated that around 33 million people are estimated to be affected from the disease in the country. The drug is launched under the brand name Aprezo. It has received approval from DCGI for Apremilast after conducting clinical trials on the molecule as per the regulatory requirements.
Company Profile : Glenmark Pharma Ltd
Leave a Reply